HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 23, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that its wholly-owned subsidiary, Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”), has resolved all cases involving the Company in connection with the multi-year
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 22, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2020 , after the close of market on Wednesday, July 29, 2020 .
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jun. 19, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2020 , filed with the Securities and Exchange Commission (the “SEC”), is available within
Earnings Call to be Conducted Wednesday, May 20 at 8:00 am ET HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2020, on Tuesday, May 19, 2020.
HAWTHORNE, N.Y. --(BUSINESS WIRE)--May 19, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2020 . Quarter ended March 31, 2020 Highlights ─ compared to March 31, 2019 Net sales of
Earnings Call to be Conducted Wednesday, May 20 at 8:00 am ET HAWTHORNE, N.Y. --(BUSINESS WIRE)--May 12, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2020 , on Tuesday, May 19, 2020 .
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Apr. 6, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced the appointment of Daphne Huang as Vice President, CFO and Chief Accounting Officer, effective today. Ms. Huang has over 20 years of senior executive
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Feb. 20, 2020-- Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling two (2) lots of Phenytoin Oral Suspension USP, 125 mg/5 mL both in 237 mL bottles, to the consumer level. Phenytoin Oral Suspension USP, 125 mg/5 mL is indicated
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Feb. 3, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2019 . Quarter ended December 31, 2019 Highlights ─ compared to December 31, 2018
Alerts are e-mailed to you whenever certain new company information is posted to this site.
